Acorda Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Acorda Therapeutics's estimated annual revenue is currently $130.3M per year.
- Acorda Therapeutics's estimated revenue per employee is $455,455
- Acorda Therapeutics's total funding is $156.6M.
- Acorda Therapeutics's current valuation is $23.9M. (January 2022)
Employee Data
- Acorda Therapeutics has 286 Employees.
- Acorda Therapeutics grew their employee count by 1% last year.
Acorda Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Sr. VP, Corporate Communications | Reveal Email/Phone |
3 | EVP Human Resources | Reveal Email/Phone |
4 | SVP - Business Development | Reveal Email/Phone |
5 | EVP, Sales, Market Access, and Operations | Reveal Email/Phone |
6 | VP Marketing | Reveal Email/Phone |
7 | SVP, Legal and Interim Chief Compliance Officer | Reveal Email/Phone |
8 | Sr. VP - HR | Reveal Email/Phone |
9 | VP Information Technology | Reveal Email/Phone |
10 | VP Quality | Reveal Email/Phone |
Acorda Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Acorda Therapeutics?
Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS. Acorda's technology platform includes two remyelinating agents in preclinical development for MS. They include M1, a class of human monoclonal antibodies, and GGF2, a product of the neuregulin 1 gene. Both agents have been shown to restore myelin in the brain and spinal cord in animal models of MS. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
keywords:N/A
$156.6M
Total Funding
286
Number of Employees
$130.3M
Revenue (est)
1%
Employee Growth %
$23.9M
Valuation
N/A
Accelerator
Acorda Therapeutics News
StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR Get Rating) in a research report issued on Tuesday.
Acorda Therapeutics; Elan Pharma; Biogen; Sun Pharmaceutical; Aurobindo Pharma. Geographicalregions: North America (United States, Canada and...
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
–Chrono Therapeutics, a Bay Area digital smoking cessation startup –Innocoll, an Irish maker of biodegradable surgical implants and topical adhesives to treat post-op pain and diabetic foot ulcers. Its previous investments include: –Civitas Therapeutics, which was acquired by Acorda Therapeut ...
The company’s had a dozen exits in the same number of months, many of which high profile – portfolio company Labrys Biologics, for instance, was acquired by Teva Pharmaceutical for up to $825 million and Citivas Therapeutics is pending acquisition from Acorda Therapeutics for $525 million. “Our ...